Treatment Algorithm for Limited-Stage Small Cell Lung Cancer

Treatment with tarlatamab demonstrated intracranial responses in a real-world cohort of patients with extensive-stage small cell lung cancer.

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

The addition of angiogenesis inhibition to immunochemotherapy for untreated extensive-stage small cell lung cancer did not significantly increase toxicity.

Experts from Washington University in St. Louis discuss prior data and strategies for mitigating toxicities like CRS associated with tarlatamab in SCLC.

The frequency and severity of adverse effects for the combination were consistent with expected safety findings for each individual agent.

Data from the phase 3 ASTRUM-005 trial support the MHRA’s approval of serplulimab for patients with extensive-stage small cell lung cancer.